Since then, FGF14 has been indicated by several linkage and genome wide association studies (GWAS) to be a putative risk factor for other neuropsychiatric diseases including depression, addiction and schizophrenia, as well as neurodegenerative diseases, such as Alzheimer’s Disease (Detera-Wadleigh et al., 1999; Park et al., 2004; Mulle et al., 2005; Need et al., 2009; Johnson et al., 2011; Verbeek et al., 2012; Singh and Rajeswari, 2015; Yang et al., 2015). This evidence concerns the gene FGF14 and depressive symptom measurement.